<html><head></head><body><h1>Fluorescein and Benoxinate Ophthalmic Solution</h1><p class="drug-subtitle"><b>Generic Name:</b> fluorescein sodium and benoxinate hydrochloride<br/>
<b>Dosage Form:</b> ophthalmic solution<br/></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li><b class="nav-item here">Professional</b></li>
<li>Interactions</li>
<li class="nav-more">
More&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewBox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/body&gt;&lt;/html&gt;
</li>
</ul><ul>
<li>Indications and Usage</li>
<li>Dosage and Administration</li>
<li>Dosage Forms and Strengths</li>
<li>Contraindications</li>
<li>Warnings and Precautions</li>
<li>Adverse Reactions/Side Effects</li>
<li>Use In Specific Populations</li>
<li class="ddc-toggle-hidden">Description</li>
<li class="ddc-toggle-hidden">Clinical Pharmacology</li>
<li class="ddc-toggle-hidden">Nonclinical Toxicology</li>
<li class="ddc-toggle-hidden">Clinical Studies</li>
<li class="ddc-toggle-hidden">How Supplied/Storage and Handling</li>
<li class="ddc-toggle-hidden">Patient Counseling Information</li>
</ul><h2>Indications and Usage for Fluorescein and Benoxinate Ophthalmic Solution</h2><p class="First">Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent.</p><h2>Fluorescein and Benoxinate Ophthalmic Solution Dosage and Administration</h2><p class="First">Instill 1 to 2 drops topically in the eye as needed.</p><h2>Dosage Forms and Strengths</h2><p class="First">Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is a yellow to orange-red ophthalmic solution containing fluorescein sodium 2.6 mg/mL (0.3%) and benoxinate hydrochloride 4.4 mg/mL (0.4%).</p><h2>Contraindications</h2><p class="First">Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is contraindicated in patients with known hypersensitivity to any component of this product.</p><h2>Warnings and Precautions</h2><h3>Corneal Toxicity</h3><p class="First">Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage with accompanying visual loss.</p><h3>Corneal Injury due to Insensitivity</h3><p class="First">Patients should not touch the eye for approximately 20 minutes after using this anesthetic as accidental injuries can occur due to insensitivity of the eye.</p><h2>Adverse Reactions</h2><p class="First">The following serious ocular adverse reactions are described elsewhere in the labeling:</p><p>The following adverse reactions have been identified following use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4%: ocular hyperemia, burning, stinging, eye irritation, blurred vision and punctate keratitis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><h2>USE IN SPECIFIC POPULATIONS</h2><h3>Pregnancy</h3><h3>Lactation</h3><h3>Pediatric Use</h3><p class="First">The safety and effectiveness of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% have been established for pediatric patients. Use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is supported in pediatric patients by evidence from adequate and well controlled studies.</p><h3>Geriatric Use</h3><p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p><h2>Fluorescein and Benoxinate Ophthalmic Solution Description</h2><p class="First">Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is a sterile solution containing a disclosing agent in combination with a short-acting ester anesthetic for topical ophthalmic use.</p><p>Fluorescein sodium is represented by the following structural formula:</p><p>Chemical Name: 3’,6’ Dihydroxy-3H-spiro[isobenzofuran-1,9-xanthen]-3-one disodium salt.</p><p>Benoxinate hydrochloride is represented by the following structural formula:</p><p>Chemical Name: 2-(Diethylamino) ethyl 4-amino-3-butoxybenzoate hydrochloride.</p><p>Each mL of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution 0.3%/0.4% contains:</p><h2>Fluorescein and Benoxinate Ophthalmic Solution - Clinical Pharmacology</h2><h3>Pharmacodynamics</h3><p class="First">Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration. The anesthetic effect may be extended by subsequent administration 10-20 minutes after the last administration.</p><h2>Nonclinical Toxicology</h2><h3>Carcinogenesis, Mutagenesis, Impairment of Fertility</h3><p class="First">Studies to evaluate the mutagenic or carcinogenic potential of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% have not been conducted. Studies to evaluate impairment of fertility have not been conducted.</p><h2>Clinical Studies</h2><p class="First">Controlled clinical studies in adults and pediatric patients have demonstrated that topical administration of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% enables visualization and corneal anesthesia sufficient to enable applanation tonometry, tear fluid dynamics evaluation and short conjunctival and corneal procedures. Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration.</p><h2>How Supplied/Storage and Handling</h2><p class="First">Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is supplied as a sterile, aqueous, topical ophthalmic solution with a fill volume of 5 mL in a 6 mL amber glass bottle and a black polypropylene cap with a sterilized rubber dropper bulb and glass pipette.</p><p><span class="Bold">NDC 24208-734-05</span></p><p><span class="Bold">Storage</span>: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. After opening, Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% can be stored up to one month if stored at room temperature or until the expiration date on the bottle if stored in refrigerated conditions. Keep tightly closed.</p><h2>Patient Counseling Information</h2><p class="First"><span class="Bold">Accidental Injury Precaution</span></p><p>Advise patients not to touch their eyes for approximately 20 minutes after application. Their eyes will be insensitive due to the effect of the anesthetic, and care should be taken to avoid accidental injuries.</p><p>Manufactured for and Distributed by:</p><p>Paragon BioTeck, Inc.</p><p>4640 SW Macadam Ave, Ste 80</p><p>Portland, OR 97239</p><p>Manufactured by:</p><p>Siegfried-Irvine,</p><p>9342 Jeronimo Road,</p><p>Irvine, CA 92618</p><h2>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h2><p class="First">NDC 24208-734-05</p><p>Paragon<br/>
BioTeck, Inc.</p><p>Fluorescein<br/>
Sodium and<br/>
Benoxinate<br/>
Hydrochloride<br/>
Ophthalmic<br/>
Solution,<br/>
0.3%/0/4%</p><p>Rx Only</p><p>5 mL</p><h2>More about benoxinate / fluorescein ophthalmic</h2><ul class="more-resources-list more-resources-list-general">
<li>Drug Interactions</li>
<li>Drug class: ophthalmic diagnostic agents</li>
</ul><h3>Professional resources</h3><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>